Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
Use of multicriteria analysis (MCA) for sustainable hydropower planning and management.

Journal of environmental management

Vassoney E, Mammoliti Mochet A, Comoglio C.
PMID: 28284137
J Environ Manage. 2017 Jul 01;196:48-55. doi: 10.1016/j.jenvman.2017.02.067. Epub 2017 Mar 08.

Multicriteria analysis (MCA) is a decision-making tool applied to a wide range of environmental management problems, including renewable energy planning and management. An interesting field of application of MCA is the evaluation and analysis of the conflicting aspects of...

Cite
Vassoney E, Mammoliti Mochet A, Comoglio C. Use of multicriteria analysis (MCA) for sustainable hydropower planning and management. J Environ Manage. 2017;196:48-55doi: 10.1016/j.jenvman.2017.02.067.
Vassoney, E., Mammoliti Mochet, A., & Comoglio, C. (2017). Use of multicriteria analysis (MCA) for sustainable hydropower planning and management. Journal of environmental management, 19648-55. https://doi.org/10.1016/j.jenvman.2017.02.067
Vassoney, Erica, et al. "Use of multicriteria analysis (MCA) for sustainable hydropower planning and management." Journal of environmental management vol. 196 (2017): 48-55. doi: https://doi.org/10.1016/j.jenvman.2017.02.067
Vassoney E, Mammoliti Mochet A, Comoglio C. Use of multicriteria analysis (MCA) for sustainable hydropower planning and management. J Environ Manage. 2017 Jul 01;196:48-55. doi: 10.1016/j.jenvman.2017.02.067. Epub 2017 Mar 08. PMID: 28284137.
Copy Download .nbib Format: NLM
Negative effects of high glucose exposure in human gonadotropin-releasing hormone neurons.

International journal of endocrinology

Morelli A, Comeglio P, Sarchielli E, Cellai I, Vignozzi L, Vannelli GB, Maggi M.
PMID: 24489542
Int J Endocrinol. 2013;2013:684659. doi: 10.1155/2013/684659. Epub 2013 Dec 31.

Metabolic disorders are often associated with male hypogonadotropic hypogonadism, suggesting that hypothalamic defects involving GnRH neurons may impair the reproductive function. Among metabolic factors hyperglycemia has been implicated in the control of the reproductive axis at central level, both...

Cite
Morelli A, Comeglio P, Sarchielli E, et al. Negative effects of high glucose exposure in human gonadotropin-releasing hormone neurons. Int J Endocrinol. 2013;2013:684659doi: 10.1155/2013/684659.
Morelli, A., Comeglio, P., Sarchielli, E., Cellai, I., Vignozzi, L., Vannelli, G. B., & Maggi, M. (2013). Negative effects of high glucose exposure in human gonadotropin-releasing hormone neurons. International journal of endocrinology, 2013684659. https://doi.org/10.1155/2013/684659
Morelli, Annamaria, et al. "Negative effects of high glucose exposure in human gonadotropin-releasing hormone neurons." International journal of endocrinology vol. 2013 (2013): 684659. doi: https://doi.org/10.1155/2013/684659
Morelli A, Comeglio P, Sarchielli E, Cellai I, Vignozzi L, Vannelli GB, Maggi M. Negative effects of high glucose exposure in human gonadotropin-releasing hormone neurons. Int J Endocrinol. 2013;2013:684659. doi: 10.1155/2013/684659. Epub 2013 Dec 31. PMID: 24489542; PMCID: PMC3893744.
Copy Download .nbib Format: NLM
Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases.

European heart journal supplements : journal of the European Society of Cardiology

Bianca I, Geraci G, Gulizia MM, Egidy Assenza G, Barone C, Campisi M, Alaimo A, Adorisio R, Comoglio F, Favilli S, Agnoletti G, Carmina MG, Chessa M, Sarubbi B, Mongiovì M, Russo MG, Bianca S, Canzone G, Bonvicini M, Viora E, Poli M.
PMID: 28751846
Eur Heart J Suppl. 2017 May;19:D256-D292. doi: 10.1093/eurheartj/sux032. Epub 2017 May 02.

The success of cardiac surgery over the past 50 years has increased numbers and median age of survivors with congenital heart disease (CHD). Adults now represent two-thirds of patients with CHD; in the USA alone the number is estimated...

Cite
Bianca I, Geraci G, Gulizia MM, et al. Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. Eur Heart J Suppl. 2017;19:D256-D292doi: 10.1093/eurheartj/sux032.
Bianca, I., Geraci, G., Gulizia, M. M., Egidy Assenza, G., Barone, C., Campisi, M., Alaimo, A., Adorisio, R., Comoglio, F., Favilli, S., Agnoletti, G., Carmina, M. G., Chessa, M., Sarubbi, B., Mongiovì, M., Russo, M. G., Bianca, S., Canzone, G., Bonvicini, M., Viora, E., & Poli, M. (2017). Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. European heart journal supplements : journal of the European Society of Cardiology, 19D256-D292. https://doi.org/10.1093/eurheartj/sux032
Bianca, Innocenzo, et al. "Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases." European heart journal supplements : journal of the European Society of Cardiology vol. 19 (2017): D256-D292. doi: https://doi.org/10.1093/eurheartj/sux032
Bianca I, Geraci G, Gulizia MM, Egidy Assenza G, Barone C, Campisi M, Alaimo A, Adorisio R, Comoglio F, Favilli S, Agnoletti G, Carmina MG, Chessa M, Sarubbi B, Mongiovì M, Russo MG, Bianca S, Canzone G, Bonvicini M, Viora E, Poli M. Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. Eur Heart J Suppl. 2017 May;19:D256-D292. doi: 10.1093/eurheartj/sux032. Epub 2017 May 02. PMID: 28751846; PMCID: PMC5526477.
Copy Download .nbib Format: NLM
Benzo[a]pyrene impairs the migratory pattern of human gonadotropin-releasing-hormone-secreting neuroblasts.

European journal of histochemistry : EJH

Guarnieri G, Becatti M, Comeglio P, Vignozzi L, Maggi M, Vannelli GB, Morelli A.
PMID: 34459573
Eur J Histochem. 2021 Aug 13;65. doi: 10.4081/ejh.2021.3282.

Benzo[a]pyrene (BaP) is a widespread pollutant that can act as an endocrine disrupting compound (EDC) and interferes with reproductive function. The central regulatory network of the reproductive system is mediated by gonadotropin-releasing hormone (GnRH) neurons, which originate in the...

Cite
Guarnieri G, Becatti M, Comeglio P, et al. Benzo[a]pyrene impairs the migratory pattern of human gonadotropin-releasing-hormone-secreting neuroblasts. Eur J Histochem. 2021;65doi: 10.4081/ejh.2021.3282.
Guarnieri, G., Becatti, M., Comeglio, P., Vignozzi, L., Maggi, M., Vannelli, G. B., & Morelli, A. (2021). Benzo[a]pyrene impairs the migratory pattern of human gonadotropin-releasing-hormone-secreting neuroblasts. European journal of histochemistry : EJH, 65. https://doi.org/10.4081/ejh.2021.3282
Guarnieri, Giulia, et al. "Benzo[a]pyrene impairs the migratory pattern of human gonadotropin-releasing-hormone-secreting neuroblasts." European journal of histochemistry : EJH vol. 65 (2021). doi: https://doi.org/10.4081/ejh.2021.3282
Guarnieri G, Becatti M, Comeglio P, Vignozzi L, Maggi M, Vannelli GB, Morelli A. Benzo[a]pyrene impairs the migratory pattern of human gonadotropin-releasing-hormone-secreting neuroblasts. Eur J Histochem. 2021 Aug 13;65. doi: 10.4081/ejh.2021.3282. PMID: 34459573; PMCID: PMC8419627.
Copy Download .nbib Format: NLM
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.

Frontiers in immunology

Desole C, Gallo S, Vitacolonna A, Vigna E, Basilico C, Montarolo F, Zuppini F, Casanova E, Miggiano R, Ferraris DM, Bertolotto A, Comoglio PM, Crepaldi T.
PMID: 34925346
Front Immunol. 2021 Dec 03;12:775151. doi: 10.3389/fimmu.2021.775151. eCollection 2021.

The Hepatocyte growth factor (HGF) and its receptor (MET) promote several physiological activities such as tissue regeneration and protection from cell injury of epithelial, endothelial, neuronal and muscle cells. The therapeutic potential of MET activation has been scrutinized in...

Cite
Desole C, Gallo S, Vitacolonna A, et al. Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor. Front Immunol. 2021;12:775151doi: 10.3389/fimmu.2021.775151.
Desole, C., Gallo, S., Vitacolonna, A., Vigna, E., Basilico, C., Montarolo, F., Zuppini, F., Casanova, E., Miggiano, R., Ferraris, D. M., Bertolotto, A., Comoglio, P. M., & Crepaldi, T. (2021). Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor. Frontiers in immunology, 12775151. https://doi.org/10.3389/fimmu.2021.775151
Desole, Claudia, et al. "Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor." Frontiers in immunology vol. 12 (2021): 775151. doi: https://doi.org/10.3389/fimmu.2021.775151
Desole C, Gallo S, Vitacolonna A, Vigna E, Basilico C, Montarolo F, Zuppini F, Casanova E, Miggiano R, Ferraris DM, Bertolotto A, Comoglio PM, Crepaldi T. Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor. Front Immunol. 2021 Dec 03;12:775151. doi: 10.3389/fimmu.2021.775151. eCollection 2021. PMID: 34925346; PMCID: PMC8679783.
Copy Download .nbib Format: NLM
Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.

Endocrine pathology

Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, DiRenzo MF.
PMID: 12114654
Endocr Pathol. 2000;11(1):19-30. doi: 10.1385/ep:11:1:19.

The tyrosine kinase receptor encoded by the MET oncogene has the unusual property of mediating the invasive growth of epithelial cells upon binding with the hepatocyte growth factor (HGF). The MET/HGF receptor is known to be overexpressed in thyroid...

Cite
Papotti M, Olivero M, Volante M, et al. Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocr Pathol. 2000;11(1):19-30doi: 10.1385/ep:11:1:19.
Papotti, M., Olivero, M., Volante, M., Negro, F., Prat, M., Comoglio, P. M., & DiRenzo, M. F. (2000). Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocrine pathology, 11(1), 19-30. https://doi.org/10.1385/ep:11:1:19
Papotti, Mauro, et al. "Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid." Endocrine pathology vol. 11,1 (2000): 19-30. doi: https://doi.org/10.1385/ep:11:1:19
Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, DiRenzo MF. Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocr Pathol. 2000;11(1):19-30. doi: 10.1385/ep:11:1:19. PMID: 12114654.
Copy Download .nbib Format: NLM
Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis.

Cell death and differentiation

Longati P, Albero D, Comoglio PM.
PMID: 17180051
Cell Death Differ. 1996 Jan;3(1):23-8.

Hepatocyte Growth Factor (HGF) is a pleiotropic factor, capable of evoking complex biological responses such as mitogenesis, motogenesis and morphogenesis in a variety of epithelial and endothelial cells. Nonetheless, the meaning of the acronym is consistent with the key...

Cite
Longati P, Albero D, Comoglio PM. Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. Cell Death Differ. 1996;3(1):23-8
Longati, P., Albero, D., & Comoglio, P. M. (1996). Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. Cell death and differentiation, 3(1), 23-8.
Longati, P, et al. "Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis." Cell death and differentiation vol. 3,1 (1996): 23-8.
Longati P, Albero D, Comoglio PM. Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. Cell Death Differ. 1996 Jan;3(1):23-8. PMID: 17180051.
Copy Download .nbib Format: NLM
Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival.

International journal of molecular sciences

Hedou E, Douceau S, Chevilley A, Varangot A, Thiebaut AM, Triniac H, Bardou I, Ali C, Maillasson M, Crepaldi T, Comoglio P, Lemarchand E, Agin V, Roussel BD, Vivien D.
PMID: 34948279
Int J Mol Sci. 2021 Dec 15;22(24). doi: 10.3390/ijms222413483.

Tissue-type plasminogen activator (tPA) plays roles in the development and the plasticity of the nervous system. Here, we demonstrate in neurons, that by opposition to the single chain form (sc-tPA), the two-chains form of tPA (tc-tPA) activates the MET...

Cite
Hedou E, Douceau S, Chevilley A, et al. Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival. Int J Mol Sci. 2021;22(24)doi: 10.3390/ijms222413483.
Hedou, E., Douceau, S., Chevilley, A., Varangot, A., Thiebaut, A. M., Triniac, H., Bardou, I., Ali, C., Maillasson, M., Crepaldi, T., Comoglio, P., Lemarchand, E., Agin, V., Roussel, B. D., & Vivien, D. (2021). Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival. International journal of molecular sciences, 22(24), . https://doi.org/10.3390/ijms222413483
Hedou, Elodie, et al. "Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival." International journal of molecular sciences vol. 22,24 (2021). doi: https://doi.org/10.3390/ijms222413483
Hedou E, Douceau S, Chevilley A, Varangot A, Thiebaut AM, Triniac H, Bardou I, Ali C, Maillasson M, Crepaldi T, Comoglio P, Lemarchand E, Agin V, Roussel BD, Vivien D. Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival. Int J Mol Sci. 2021 Dec 15;22(24). doi: 10.3390/ijms222413483. PMID: 34948279.
Copy Download .nbib Format: NLM
Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells.

Communications biology

Penco-Campillo M, Comoglio Y, Feliz Morel ÁJ, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi M, Morot A, Burel-Vandenbos F, Selby M, Williamson D, Clifford SC, Claren A, Doyen J, Picco V, Martial S, Pagès G.
PMID: 33288846
Commun Biol. 2020 Dec 07;3(1):758. doi: 10.1038/s42003-020-01502-2.

A Correction to this paper has been published: https://doi.org/10.1038/s42003-020-01502-2.

Cite
Penco-Campillo M, Comoglio Y, Feliz Morel ÁJ, et al. Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Commun Biol. 2020;3(1):758doi: 10.1038/s42003-020-01502-2.
Penco-Campillo, M., Comoglio, Y., Feliz Morel, �. �. J., Hanna, R., Durivault, J., Leloire, M., Mejias, B., Pagnuzzi, M., Morot, A., Burel-Vandenbos, F., Selby, M., Williamson, D., Clifford, S. C., Claren, A., Doyen, J., Picco, V., Martial, S., & Pagès, G. (2020). Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Communications biology, 3(1), 758. https://doi.org/10.1038/s42003-020-01502-2
Penco-Campillo, Manon, et al. "Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells." Communications biology vol. 3,1 (2020): 758. doi: https://doi.org/10.1038/s42003-020-01502-2
Penco-Campillo M, Comoglio Y, Feliz Morel ÁJ, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi M, Morot A, Burel-Vandenbos F, Selby M, Williamson D, Clifford SC, Claren A, Doyen J, Picco V, Martial S, Pagès G. Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Commun Biol. 2020 Dec 07;3(1):758. doi: 10.1038/s42003-020-01502-2. PMID: 33288846; PMCID: PMC7721738.
Copy Download .nbib Format: NLM
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.

Blood

Wilke AC, Doebele C, Zindel A, Lee KS, Rieke SA, Ceribelli M, Comoglio F, Phelan JD, Wang JQ, Pikman Y, Jahn D, Häupl B, Schneider C, Scheich S, Tosto FA, Bohnenberger H, Stauder P, Schnuetgen F, Slabicki M, Coulibaly ZA, Wolf S, Bojarczuk K, Chapuy B, Brandts CH, Stroebel P, Lewis CA, Engelke M, Xu X, Kim H, Dang TH, Schmitz R, Hodson DJ, Stegmaier K, Urlaub H, Serve H, Schmitt CA, Kreuz F, Knittel G, Rabinowitz JD, Reinhardt HC, Vander Heiden MG, Thomas C, Staudt LM, Zenz T, Oellerich T.
PMID: 34624079
Blood. 2020 Oct 08; doi: 10.1182/blood.2021012081. Epub 2020 Oct 08.

Burkitt lymphoma (BL) is an aggressive lymphoma type that is currently treated by intensive chemoimmunotherapy. Despite the favorable clinical outcome of the majority of BL patients, chemotherapy-related toxicity and disease relapse remain as major clinical challenges, emphasizing the need...

Cite
Wilke AC, Doebele C, Zindel A, et al. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2020;doi: 10.1182/blood.2021012081.
Wilke, A. C., Doebele, C., Zindel, A., Lee, K. S., Rieke, S. A., Ceribelli, M., Comoglio, F., Phelan, J. D., Wang, J. Q., Pikman, Y., Jahn, D., Häupl, B., Schneider, C., Scheich, S., Tosto, F. A., Bohnenberger, H., Stauder, P., Schnuetgen, F., Slabicki, M., Coulibaly, Z. A., Wolf, S., Bojarczuk, K., Chapuy, B., Brandts, C. H., Stroebel, P., Lewis, C. A., Engelke, M., Xu, X., Kim, H., Dang, T. H., Schmitz, R., Hodson, D. J., Stegmaier, K., Urlaub, H., Serve, H., Schmitt, C. A., Kreuz, F., Knittel, G., Rabinowitz, J. D., Reinhardt, H. C., Vander Heiden, M. G., Thomas, C., Staudt, L. M., Zenz, T., & Oellerich, T. (2020). SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood, . https://doi.org/10.1182/blood.2021012081
Wilke, Anne C, et al. "SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma." Blood vol. (2020). doi: https://doi.org/10.1182/blood.2021012081
Wilke AC, Doebele C, Zindel A, Lee KS, Rieke SA, Ceribelli M, Comoglio F, Phelan JD, Wang JQ, Pikman Y, Jahn D, Häupl B, Schneider C, Scheich S, Tosto FA, Bohnenberger H, Stauder P, Schnuetgen F, Slabicki M, Coulibaly ZA, Wolf S, Bojarczuk K, Chapuy B, Brandts CH, Stroebel P, Lewis CA, Engelke M, Xu X, Kim H, Dang TH, Schmitz R, Hodson DJ, Stegmaier K, Urlaub H, Serve H, Schmitt CA, Kreuz F, Knittel G, Rabinowitz JD, Reinhardt HC, Vander Heiden MG, Thomas C, Staudt LM, Zenz T, Oellerich T. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2020 Oct 08; doi: 10.1182/blood.2021012081. Epub 2020 Oct 08. PMID: 34624079.
Copy Download .nbib Format: NLM
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

Cell reports

De Bacco F, Orzan F, Erriquez J, Casanova E, Barault L, Albano R, D'Ambrosio A, Bigatto V, Reato G, Patanè M, Pollo B, Kuesters G, Dell'Aglio C, Casorzo L, Pellegatta S, Finocchiaro G, Comoglio PM, Boccaccio C.
PMID: 34320350
Cell Rep. 2021 Jul 27;36(4):109455. doi: 10.1016/j.celrep.2021.109455.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based...

Cite
De Bacco F, Orzan F, Erriquez J, et al. ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Rep. 2021;36(4):109455doi: 10.1016/j.celrep.2021.109455.
De Bacco, F., Orzan, F., Erriquez, J., Casanova, E., Barault, L., Albano, R., D'Ambrosio, A., Bigatto, V., Reato, G., Patanè, M., Pollo, B., Kuesters, G., Dell'Aglio, C., Casorzo, L., Pellegatta, S., Finocchiaro, G., Comoglio, P. M., & Boccaccio, C. (2021). ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell reports, 36(4), 109455. https://doi.org/10.1016/j.celrep.2021.109455
De Bacco, Francesca, et al. "ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma." Cell reports vol. 36,4 (2021): 109455. doi: https://doi.org/10.1016/j.celrep.2021.109455
De Bacco F, Orzan F, Erriquez J, Casanova E, Barault L, Albano R, D'Ambrosio A, Bigatto V, Reato G, Patanè M, Pollo B, Kuesters G, Dell'Aglio C, Casorzo L, Pellegatta S, Finocchiaro G, Comoglio PM, Boccaccio C. ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Rep. 2021 Jul 27;36(4):109455. doi: 10.1016/j.celrep.2021.109455. PMID: 34320350.
Copy Download .nbib Format: NLM
HGF and MET: From Brain Development to Neurological Disorders.

Frontiers in cell and developmental biology

Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D, Comoglio P, Crepaldi T.
PMID: 34179015
Front Cell Dev Biol. 2021 Jun 09;9:683609. doi: 10.3389/fcell.2021.683609. eCollection 2021.

Hepatocyte growth factor (HGF) and its tyrosine kinase receptor, encoded by the MET cellular proto-oncogene, are expressed in the nervous system from pre-natal development to adult life, where they are involved in neuronal growth and survival. In this review,...

Cite
Desole C, Gallo S, Vitacolonna A, et al. HGF and MET: From Brain Development to Neurological Disorders. Front Cell Dev Biol. 2021;9:683609doi: 10.3389/fcell.2021.683609.
Desole, C., Gallo, S., Vitacolonna, A., Montarolo, F., Bertolotto, A., Vivien, D., Comoglio, P., & Crepaldi, T. (2021). HGF and MET: From Brain Development to Neurological Disorders. Frontiers in cell and developmental biology, 9683609. https://doi.org/10.3389/fcell.2021.683609
Desole, Claudia, et al. "HGF and MET: From Brain Development to Neurological Disorders." Frontiers in cell and developmental biology vol. 9 (2021): 683609. doi: https://doi.org/10.3389/fcell.2021.683609
Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D, Comoglio P, Crepaldi T. HGF and MET: From Brain Development to Neurological Disorders. Front Cell Dev Biol. 2021 Jun 09;9:683609. doi: 10.3389/fcell.2021.683609. eCollection 2021. PMID: 34179015; PMCID: PMC8220160.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries